Definitive Contract 75N91019C00004

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...

This is a Small Business Set-Aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to DiaCarta L.L.C., a minority-owned, for-profit limited liability company. The $299,698.00 firm-fixed-price contract is for a Small Business Technology Transfer (STTR) Phase I research project to develop "Predictive Biomarkers of Adverse Reactions to Radiation Treatment" over a period from September 19, 2016 to June 18, 2017. The contract does not appear to be associated with...

<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients treated with radiation therapy. The contract has a total potential value of $1,396,540.45 and a period of performance from September 19, 2016 to August 19, 2021. The contract is a cost-plus-fixed-fee Definitive Contract.</p>

<p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

<p>This is a $1,999,386.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Avoneaux Medical Institute, LLC, a veteran-owned limited liability company. The contract is for the development of spatial micropurification technology under SBIR Topic 403. The contract is a definitive, firm fixed-price contract with a period of performance ending on September 18, 2024.</p>

<p>This is a small business set-aside contract awarded by the National Cancer Institute (NCI), a civilian agency, to Dxterity Diagnostics Incorporated. The contract is for the development of a blood test to predict radiation toxicity in patients undergoing radiation therapy, as part of the Small Business Innovation Research (SBIR) program. The definitive, firm-fixed price contract has a ceiling value of $280,005.00 and a performance period ending on March 31, 2015.</p>

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This $2,399,183 firm-fixed-price SBIR Phase I contract was awarded by the National Cancer Institute (NCI) to Radiologics, Inc., a small business, to conduct research and development on cancer imaging tools and image de-identification software. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase private sector commercialization of innovations derived from federal R&amp;D. The contract has a period of performance through January 2024 and is...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Pieces Technologies Inc., a small business, under the Small Business Innovation Research (SBIR) Phase II program. The contract, worth $1,999,994.00, is for the project titled &quot;Passive and Active AI Screening for Social Determinants of Health and Interventions to Improve Outcomes in the Cancer Patient Population.&quot; The contract has a period of performance from September 16,...